• All
• Day 1: March 27 (Thu)
• Day 2: March 28 (Fri)
• Day 3: March 29 (Sat)

Day 1: March 27 (Thu)

• Opportunities and challenges in managing adult ALL in Vietnam Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Adult ALL in Armenia Armine Farmazyan
  Hematology Center after Prof. R. H. Yeolyan, Armenia CV Abstract
• Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand Weerapat Owattanapanich
  Faculty of Siriraj Hospital, Mahidol University, Thailand CV Abstract
• Adult ALL in Korea Ik Chan Song
  Chungnam National University College of Medicine, Korea CV Abstract

Day 1: March 27 (Thu)

• Diagnosis and treatment of ph-like ALL in children and young adults Thai Hoa Tran
  Université de Montréal, Canada CV Abstract
• Advances in the genetics of Down syndrome-related myeloid leukemia Etsuro Ito
  Hirosaki University Graduate School of Medicine, Japan CV Abstract
• Towards improving outcomes for high risk pediatric acute myeloid leukemia Todd Cooper
  University of Washington, USA CV Abstract

Day 1: March 27 (Thu)

• Immune therapy and the bone marrow microenvironment in multiple myeloma Hearn Jay Cho
  Icahn School of Medicine at Mount Sinai, USA CV Abstract
• Mechanisms of antigen escape after T-cell based immunotherapies Paola Neri
  University of Calgary, Canada CV Abstract
• Cellular immunotherapy platforms in multiple myeloma Sung-Hoon Jung
  Chonnam National University Medical School, Korea CV Abstract

Day 1: March 27 (Thu)

• Tracing the changes: MDS risk stratification Seo-Yeon Ahn
  Chonnam National University Medical School, Korea CV Abstract
• Managing MDS with HMAs following the AZA-001 trial Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Approved MDS treatments beyond HMAs Junshik Hong
  Seoul National University College of Medicine, Korea CV Abstract

Day 1: March 27 (Thu)

• Myeloproliferative Neoplasms: 2025 Update Ayalew Tefferi
  Mayo Clinic, USA CV

Day 1: March 27 (Thu)

• CAR T-cell Therapy for Lymphomas: Current and Future Trends Sattva S Neelapu
  The University of Texas MD Anderson Cancer Center, USA CV Abstract

Day 1: March 27 (Thu)

• Expanding Horizons in PNH Treatment: Pegcetacoplan in Proximal Inhibition Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 1: March 27 (Thu)

• Recent Insights on DLBCL Treatment: Focused on Glofitamab and Polatuzumab Andrew Davies
  University of Southampton, UK CV Abstract

Day 1: March 27 (Thu)

• Optimizing Current Treatment Strategies in Relapsed/Refractory Multiple Myeloma Wee Joo Chng
  National University of Singapore, Singapore CV Abstract

Day 1: March 27 (Thu)

• Omjjara: Redefine the Fundamental Treatment for Myelofibrosis Patients with Anemia Harry Gill
  The University of Hong Kong, Hong Kong CV Abstract

Day 1: March 27 (Thu)

• Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC) Brian Huntly
  University of Cambridge, UK CV Abstract
• Treatment of AML in Korea June-Won Cheong
  Yonsei University College of Medicine, Korea CV Abstract
• Genetics guiding treatment in AML Hartmut Döhner
  Ulm University Hospital, Germany CV Abstract
• The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study Jae-Sook Ahn
  Chonnam National University Medical School, Korea CV Abstract

Day 1: March 27 (Thu)

• When not to use direct oral anticoagulants Jeffrey I. Weitz
  McMaster University, Canada CV Abstract
• Managing patients with cancer associated venous thromboembolism Robert D. McBane II
  Mayo College of Medicine, USA CV Abstract
• Risk assessment and thromboprophylaxis for cancer-associated VTE Ingrid Pabinger-Fasching
  Medical University of Vienna, Austria CV Abstract

Day 1: March 27 (Thu)

• Turning the corner in the management of the PTCL Owen A O'Connor
  University of Virginia Comprehensive Cancer Center, USA CV Abstract
• Recent updates and future in the management of R/R PTCL Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea CV
• The development of new agents in T-cell lymphoma Hyun Jung Lee
  Kyung Hee University College of Medicine, Korea CV Abstract

Day 1: March 27 (Thu)

• AI everywhere Auk Kim
  Department of Computer Science and Engineering, Kangwon National University, Korea CV Abstract
• Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation Sang-Hyun Hwang
  University of Ulsan College of Medicine, Korea CV Abstract
• Generative AI use case for medical research: HRS (healthcare data research suite) Soo-Yong Shin
  Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea CV Abstract

Day 1: March 27 (Thu)

• Iron metabolism in JAK2-mutant myeloproliferative neoplasms Radek C. Skoda
  Dan L Duncan Comprehensive Cancer Center, USA CV Abstract
• Hepcidin in the pathophysiology of and as treatment for polycythemia vera Yelena Z. Ginzburg
  Icahn School of Medicine at Mount Sinai, USA CV Abstract
• Anemia and JAK inhibitors Jean-Jaques Kiladjian
  Hôpital Saint-Louis, France CV Abstract

Day 1: March 27 (Thu)

• Innovations in HLH therapy: Beyond HLH94 Michelle Hermiston
  VinUniversity, Vietnam / UCSF, USA CV Abstract
• Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies Oussama Abla
  The Hospital for Sick Children, Canada CV Abstract
• From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes Melissa Hines
  St. Jude Children’s Research Hospital, USA CV Abstract

Day 1: March 27 (Thu)

• Understanding and overcoming resistance in AML Dong-Yeop Shin
  Seoul National University College of Medicine, Korea CV Abstract
• Exploring immune checkpoint targets beyond PD-1 and PD-L1 in AML (LAIR-1 agonism as a novel therapy for acute myeloid leukemia) Tae Kon Kim
  Vanderbilt University Medical Center, USA CV Abstract
• Implementing a functional precision medicine for AML patients Mika Kontro
  Helsinki University Hospital, Finland CV Abstract

Day 1: March 27 (Thu)

• Crafting a successful investigator-initiated study proposal: Key elements and strategies Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Current trends of big data research using the Korean national health information database Kyungdo Han
  Department of Statistics and Actuarial Science, Soongsil University, Korea CV Abstract
• Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting Jeong-Ok Lee
  Seoul National University College of Medicine, Korea CV Abstract